Oil prices hold sharp losses with focus on secondary India tariffs
Monday, Repligen Corporation (NASDAQ:RGEN) received a reaffirmed Hold rating from Benchmark, with the firm’s analyst Robert Wasserman maintaining the price target on the company’s shares. Wasserman’s commentary followed Repligen’s disclosure of its financial outcomes for the fourth quarter of 2024, which showed a slight revenue increase to $167.5 million, a 1% rise from the previous year. The company’s adjusted earnings per share (EPS) for the quarter were reported at $0.44, a slight decrease from $0.48 in the fourth quarter of 2023. According to InvestingPro data, the company currently operates with a moderate debt level and has achieved a significant 8.2% return over the last week, despite challenging market conditions.
Repligen’s financial performance fell short of Benchmark’s expectations, which had projected revenues of $172.0 million and an adjusted EPS of $0.50. Despite this, the company experienced a notable 11% increase in orders during the quarter. The company maintains a solid gross profit margin of 50.4%, though this positive aspect was somewhat balanced by a decline in adjusted gross margins, as noted by the analyst. InvestingPro analysis reveals 8 additional key insights about Repligen’s financial health and market position, available to subscribers.
Looking ahead, Repligen’s management has provided guidance for the full year of 2025, anticipating a revenue growth of 10%-14%, excluding any impact from COVID-19, and projecting an adjusted EPS in the range of $1.67 to $1.76. This guidance suggests an optimistic outlook, considering the adjusted EPS for 2024 was reported at $1.58.
In light of the recent financial report and forward guidance, Benchmark has decided to maintain a Hold rating on Repligen stock. The firm’s stance reflects a view that the company’s business is stabilizing after the disruptions caused by the pandemic. Wasserman’s analysis suggests that while Repligen is showing signs of steady operational performance, the current financial metrics do not warrant a change in the stock’s rating at this time.
In other recent news, Repligen Corporation has announced its fourth-quarter and full-year financial results for 2024, with fourth-quarter revenue reaching $167.5 million and full-year revenue totaling $634.4 million, aligning with expectations from analysts like H.C. Wainwright. The company has set its 2025 revenue guidance between $685 million and $710 million, slightly above the consensus forecast. Repligen also reported a 13% organic growth in the fourth quarter, excluding COVID-related impacts, and saw a 6% increase in orders over sales, driven by demand in its Filtration and Analytics franchises.
The company completed the acquisition of Tantti Laboratory Inc., enhancing its offerings in protein and chromatography, and launched AVIPure dsRNA resin, a new product aimed at mRNA-based therapeutics. Analyst firms have responded to these developments, with H.C. Wainwright maintaining a Buy rating and a $180 price target, while KeyBanc reiterated an Overweight rating with a $220 target. Meanwhile, Canaccord Genuity and Jefferies have adjusted their price targets to $170 and $165, respectively, maintaining a Hold rating.
Repligen’s strategic initiatives and strong order momentum have been noted by analysts as key factors in its positive outlook for 2025. The company’s focus on expanding its product offerings and commitment to innovation are expected to contribute to its growth in the bioprocessing market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.